On November 1, Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as “Leads Biolabs”) announced that LBL-034, a humanized bispecific T-cell engaging antibody targeting both GPRC5D and CD3 which ...
Fortress Biotech, Inc. (NASDAQ: FBIO) announced through its majority-controlled subsidiary, Journey Medical Corporation, that the U.S. Food and Drug Administration (FDA) has approved Emrosi™ ...
“You’re sharing your trauma journey ... was not using the drug to treat a mental health problem, Ghaemi said many are seeking ...
Journey Medical's new rosacea treatment will rival industry giant Galderma's Oracea in the treatment of rosacea.
Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...
Key trial focus: PK/PD in healthy subjects, with PK bracketed by standard epinephrine injections No placebo-controlled efficacy studies required NORTH HAVEN, Conn., Nov. 05, 2024 (GLOBE NEWSWIRE) -- ...
Recent health news covers Vertex Pharmaceuticals' revenue uptick due to cystic fibrosis treatments, Britain's detection of ...
Her journey began conventionally ... this form of medical experimentation may be short-lived. Once shortages ease, companies ...
Journey Medical (DERM) received FDA approval for its drug Emrosi for the treatment of rosacea and released its preliminary Q3 ...
The U.S. Food and Drug Administration took Zepbound off its shortage list in early October. Last week, the agency also listed all doses of Wegovy as available, though it has yet to come off the ...
These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback